These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 18259162)

  • 21. Where the money is.
    Fitzgerald M
    Nat Biotechnol; 2006 Mar; 24(3):240-2. PubMed ID: 16525370
    [No Abstract]   [Full Text] [Related]  

  • 22. US credit crunch impacts biotech across the globe.
    Mitchell P
    Nat Biotechnol; 2008 Apr; 26(4):359-60. PubMed ID: 18391997
    [No Abstract]   [Full Text] [Related]  

  • 23. Public biotech 2007--the numbers.
    Lawrence S; Lähteenmäki R
    Nat Biotechnol; 2008 Jul; 26(7):753-62. PubMed ID: 18612294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early-stage returns?
    Booth BL
    Nat Biotechnol; 2006 Nov; 24(11):1335-40. PubMed ID: 17093473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hedge funds gain edge by doubling biotech investments.
    Ransom J
    Nat Biotechnol; 2006 Apr; 24(4):373-4. PubMed ID: 16601707
    [No Abstract]   [Full Text] [Related]  

  • 26. Biotech holds steady in Q4.
    Mitchell P
    Nat Biotechnol; 2004 Feb; 22(2):135-6. PubMed ID: 14755275
    [No Abstract]   [Full Text] [Related]  

  • 27. Public biotech 2013--the numbers.
    Lawrence S; Lahteenmaki R
    Nat Biotechnol; 2014 Jul; 32(7):626-32. PubMed ID: 25004227
    [No Abstract]   [Full Text] [Related]  

  • 28. Mixed results in Q1.
    Lawrence S
    Nat Biotechnol; 2005 May; 23(5):518. PubMed ID: 15877059
    [No Abstract]   [Full Text] [Related]  

  • 29. Biotech IPOs--flop or pop?
    Jacobs T
    Nat Biotechnol; 2004 Aug; 22(8):949. PubMed ID: 15286641
    [No Abstract]   [Full Text] [Related]  

  • 30. The responsibilities of growing up.
    Nat Biotechnol; 2006 Mar; 24(3):225. PubMed ID: 16525362
    [No Abstract]   [Full Text] [Related]  

  • 31. The 802 million dollars fallacy.
    Hodgson J
    Nat Biotechnol; 2004 Sep; 22(9):1076. PubMed ID: 15340464
    [No Abstract]   [Full Text] [Related]  

  • 32. The stampede to convertibles.
    Jacobs T
    Nat Biotechnol; 2003 Aug; 21(8):855. PubMed ID: 12894195
    [No Abstract]   [Full Text] [Related]  

  • 33. Sustaining agbiotechnology through lean times.
    McElroy D
    Nat Biotechnol; 2003 Sep; 21(9):996-1002. PubMed ID: 12949560
    [No Abstract]   [Full Text] [Related]  

  • 34. The death spiral.
    Nat Biotechnol; 2006 Jun; 24(6):594. PubMed ID: 16763571
    [No Abstract]   [Full Text] [Related]  

  • 35. When less is more.
    Booth BL
    Nat Biotechnol; 2007 Aug; 25(8):853-7. PubMed ID: 17687357
    [No Abstract]   [Full Text] [Related]  

  • 36. Biotech sector ponders potential 'bloodbath'.
    Mitchell P
    Nat Biotechnol; 2009 Jan; 27(1):3-4. PubMed ID: 19131974
    [No Abstract]   [Full Text] [Related]  

  • 37. The German MedTech industry in 2007.
    Schmitt JM; Beeres M
    Med Device Technol; 2007; 18(7):56. PubMed ID: 18075138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IPOs break $1 billion in Q2.
    Lawrence S
    Nat Biotechnol; 2007 Aug; 25(8):833. PubMed ID: 17687349
    [No Abstract]   [Full Text] [Related]  

  • 39. Evolving symbiosis--venture capital and biotechnology.
    Bradford TC
    Nat Biotechnol; 2003 Sep; 21(9):983-4. PubMed ID: 12949556
    [No Abstract]   [Full Text] [Related]  

  • 40. Public biotech 2010--the numbers.
    Huggett B; Hodgson J; Lähteenmäki R
    Nat Biotechnol; 2011 Jul; 29(7):585-91. PubMed ID: 21747381
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.